Cyclin Dependent Kinase 4 – Pipeline Review, H2 2019

Global Markets Direct’s, 'Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)- Pipeline Review, H2 2019’, provides in depth analysis on Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Metabolic Disorders and Toxicology under development targeting Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

– The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharm Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Pharmaceutical Group Co Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

Tiziana Life Sciences Plc

ViroStatics SRL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharm Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Pharmaceutical Group Co Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

Tiziana Life Sciences Plc

ViroStatics SRL

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-16350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-3002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit CDK4 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-437c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-10342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JS-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lerociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-108110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06873600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4/6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TQ-05510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trilaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-2370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-3287 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Product Development Milestones

Featured News & Press Releases

Dec 11, 2019: Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

Dec 11, 2019: G1 Therapeutics presents updated data from phase 1b/2a trial of oral CDK4/6 inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

Dec 11, 2019: Combining endocrine therapy with a CDK4/6 Inhibitor results in similar response rates to chemotherapy for high-risk Luminal B Breast Cancer

Dec 08, 2019: New test predicts chance of living more than a year on targeted breast cancer treatment

Nov 28, 2019: NICE recommends Pfizer’s Ibrance for NHS use through the CDF

Nov 11, 2019: Novartis’ Kisqali (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium (SMC) for the treatment of patients with the most common form of advanced breast cancer

Oct 03, 2019: MEI pharma announces updated clinical data from voruciclib

Sep 30, 2019: ESMO 2019: Kisqali shows superior overall survival in breast cancer

Sep 29, 2019: Verzenio (abemaciclib) significantly extends life by a Median of

9.4 months for women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 study

Sep 28, 2019: G1 Therapeutics presents updated data at ESMO 2019 from randomized phase 2 trial of Trilaciclib in combination with chemotherapy in metastatic triple-negative breast cancer demonstrating significant improvement in overall survival

Sep 26, 2019: Addition of KISQALI to drug plan in Quebec expands access to treatment for metastatic breast cancer

Sep 24, 2019: Pfizer presents new evidence of IBRANCE (palbociclib) effectiveness in HR+, HER2- metastatic breast cancer patients in four real-world studies at ESMO Congress 2019

Sep 23, 2019: Lilly Oncology to present robust data on VERZENIO (abemaciclib) at ESMO 2019

Sep 10, 2019: G1 Therapeutics to present new clinical data on Lerociclib (G1T38) at European Society for Medical Oncology (ESMO) 2019 Congress

Sep 10, 2019: G1 Therapeutics to present new clinical data on Trilaciclib at European Society for Medical Oncology (ESMO) 2019 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Beta Pharma Inc, H2 2019

Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by ESSA Pharma Inc, H2 2019

Pipeline by Fochon Pharmaceutical Ltd, H2 2019

Pipeline by G1 Therapeutics Inc, H2 2019

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H2 2019

Pipeline by HEC Pharm Co Ltd, H2 2019

Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2019

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Pipeline by MEI Pharma Inc, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Onconova Therapeutics Inc, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019

Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019

Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019

Pipeline by Shanghai Pharmaceutical Group Co Ltd, H2 2019

Pipeline by SignalRx Pharmaceuticals Inc, H2 2019

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2019

Pipeline by Sino Biopharmaceutical Ltd, H2 2019

Pipeline by Tetranov International Inc, H2 2019

Pipeline by Tiziana Life Sciences Plc, H2 2019

Pipeline by ViroStatics SRL, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports